Physician profile
Faisal E Haq
NPI 1023044658
$3,163.63
in general payments reported to CMS, 2019-2025
27 companies · $671 in 2025
The $671 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $922 · 2020: $273 · 2021: $237 · 2022: $505 · 2023: $241 · 2024: $314 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $684.51 | 2019-2025 | Wavelight Sightmap, Rocklatan, Tryptyr |
| Abbvie INC. | $373.68 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $357.05 | 2019-2024 | Tecnis Simplicity, Tecnis Iol |
| Biotissue Holdings INC. | $276.30 | 2022-2023 | |
| Rxsight INC | $180.29 | 2021-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Ivantis, INC | $155.65 | 2019 | |
| Allergan, INC. | $152.11 | 2019-2021 | |
| Alcon Research LLC | $134.41 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $111.69 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $89.45 | 2019-2022 | |
| Astellas Pharma US INC | $84.60 | 2024-2025 | Izervay |
| Aerie Pharmaceuticals, INC. | $83.00 | 2019-2020 | |
| Harrow Eye, LLC | $73.96 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $55.22 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $47.62 | 2022-2024 | Vyzulta, Lotemax Sm, Miebo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $42.52 | 2022-2024 | Omni Surgical System |
| Thea Pharma INC. | $34.71 | 2024 | Iyuzeh |
| Rayner Intraocular Lenses Limited | $34.61 | 2024-2025 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
| Glaukos Corporation | $32.66 | 2025 | Idosetr |
| Oyster Point Pharma, INC. | $29.01 | 2023 | Tyrvaya |
| Dompe US, INC. | $23.82 | 2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $22.32 | 2021 | |
| Apellis Pharmaceuticals, INC. | $20.95 | 2025 | Syfovre |
| Kala Pharmaceuticals, INC. | $17.32 | 2019 | |
| Eyepoint US, INC. | $16.80 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $16.38 | 2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $12.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faisal Haq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.